Cybin is conducting clinical trials with a number of tryptamines to treat a plethora of disorders. Today it was awarded

Last year MAPS completed its Phase IIIa trials with MDMA in the treatment of PTSD. The subsequent data release grabbed

2021 was a seminal year for psychedelic medicine, with data released from groundbreaking clinical trials harnessing MDMA and psilocybin. The

To alter public perception and promote the acceptance of psychedelics as medicines, Gwella launched Mojo – a functional mushroom product

For psychedelic medicines to reach as many patients as possible, developers need to secure buy-in at every level of the

Awakn Life Sciences recently signed a memorandum of understanding with Devon Partnership NHS Trust and the University of Exeter, to

In 2021, psychedelic medicines moved from the frontiers of scientific research to the front pages of newspapers worldwide. This was

To strengthen the adoption of psychedelic-assisted therapies, drug developers are striving to minimise their cost – with shorter lasting tryptamines.

Member of Parliament Crispin Blunt has championed the campaign to reschedule psilocybin for scientific and research purposes in the UK.

This week COMPASS Pathways provided an eagerly anticipated update from its Phase IIb clinical trial. The largest ever study with

Cybin became the first psychedelic healthcare company to list on the New York Stock Exchange, with its psilocybin formulation to

At Prime Minister’s Questions on 19 October, Boris Johnson responded to Tory MP Crispin Blunt’s call to reschedule psilocybin. Johnson